News

Drug Briefing: Elacestrant

Views: 60     Author: Unibest Industrial     Publish Time: 2024-10-08      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
sharethis sharing button


Query Drug:Elacestrant

Query Time:2024-10-08 16:20:43

*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.


About the Drug

Elacestrant is used to treat advanced hormone-related breast cancer in postmenopausal women and adult men when cancer has progressed or has spread to other parts of the body (metastatic) after other treatments have failed.

Your doctor will make sure you have the correct tumor type to be treated with elacestrant.

Elacestrant may also be used for purposes not listed in this medication guide.

Related Diseases

Extra Information on Drug and Diseases

Drug elacestrant

RXCUI: 2628469

    Drug elacestrant dihydrochloride

    RXCUI: 2628473

    May Treat

    • Breast Neoplasms

    Similar Drugs

    [may_treat] Breast Neoplasms

    Source MEDRT

    [Mechanism of Action] Estrogen Receptor Antagonists

    Source MEDRT

    [Physiological Effect] Increased Protein Breakdown

    Source: MEDRT

    [Physiological Effect] Cellular Proliferation Alteration

    Source: MEDRT

    Orange Book

    [Last update] 2024-08-09

    Labelers

    Elacestrant's Innovator is STEMLINE THERAPEUTICS INC

    Drug Products

    The unique dosage forms from the innovator include:1. TABLET;ORAL.

    Index Route Brand Name Labeler Approval Date Dosage
    1 TABLET;ORAL ORSERDU STEMLINE THERAPEUTICS INC Jan 27, 2023 EQ 345MG BASE
    2 TABLET;ORAL ORSERDU STEMLINE THERAPEUTICS INC Jan 27, 2023 EQ 86MG BASE

    Drug Patents

    This drug still has 8 effective patents.

    Patent Number Submission Date Expiration Date Drug Substance Patent? Drug Product Patent?
    10071066 Feb 24, 2023 Oct 10, 2034

    8399520 Feb 24, 2023 Dec 25, 2024 Y Y
    10745343 Feb 24, 2023 Jan 5, 2038

    10420734 Mar 10, 2023 Oct 10, 2034

    7612114 Mar 10, 2023 Aug 18, 2026 Y Y
    10385008 Mar 10, 2023 Jan 5, 2038 Y Y
    11779552 Nov 6, 2023 Oct 10, 2034

    11819480 Dec 21, 2023 Nov 29, 2036

    Elacestrant Patent Scope

    Related Company's Product Pipelines

    The innovator STEMLINE THERAPEUTICS INC's portolio contains products with the following 1 API(s): ELACESTRANT DIHYDROCHLORIDE

    The above products are related to 1 diseases: Breast Neoplasms

    STEMLINE THERAPEUTICS INC Diseases Covered